No Data
Summit Extends Gains as Cancer Drug Outperforms BeiGene's Tevimbra
Zai Lab To Present Data From Phase 1 Trial Of DLL3-Targeted Antibody-Drug Conjugate ZL-1310 At 2025 ASCO Annual Meeting
2024 Annual Report
Summit Therapeutics' Partner Akeso HARMONi-6/AK112-306 Phase 3 Trial Of Ivonescimab In Combination With Platinum-based Chemotherapy Compared With Tislelizumab Met Its Primary Endpoint Of Progression-Free Survival For Locally Advanced Or Metastatic...
JP Morgan Maintains Overweight on BeiGene, Raises Price Target to $317
Has the SSE Health Care theme Index risen again? This year, the public fund performance has shuffled, with the highest return of the health care theme Fund exceeding 44%, and Inflow of capital has accelerated.
As of April 16, two SSE Health Care theme Index Funds have entered the top 10 performances of actively managed equity funds this year; Since April, multiple Hwabao WP CSI Medical Service ETFs have seen significant net subscriptions, with the total amount of fund shares for these medical ETFs reaching a new high; Fund managers believe that the pharmaceutical sector is not just undervalued in parts, but is comprehensively undervalued, and the nature of Innovative Drugs has changed.
